Article 9(4) of Directive 2004/48/EC obliges Member States to ensure that courts may issue provisional measures, including injunctions, without giving prior notice to the defendant in certain…
Much like Black Sabbath’s iconic track "Paranoid"—an anthem whose unsettling riffs once left skeptics bewildered—I find myself contemplating the equally discordant landscape of Standard Essential…
In the UK, as well as in many other countries, being the first to market with a generic or biosimilar to a leading branded medicine is a critical strategy that can offer a major advantage to a…
As is well known in the life sciences community in Europe, both the Commission and the Parliament have proposed reforms to the Medicines Directive which, if implemented, would serve to broaden the…
Standard Essential Patents (SEPs) are at the heart of global technology markets, particularly in 4G/5G communications. While SEPs ensure interoperability, they also raise significant licensing…
A famous joke that must now be over 30 years old quips about the strength of the (German) patent attorney profession: „If all German patent attorneys and their families decide to settle in a single…
“I still haven’t found what I’m looking for.” U2’s iconic lyric might capture how patent holders feel when an anti-suit injunction (ASI) from a foreign court threatens to derail enforcement in Europe…
G 1/24 addresses the extent to which the description can be used to interpret the claims. As previously discussed, it looks set to be one of the most consequential EPO decisions of the decade. The…
Back in January 2025, the EU initiated consultations at the World Trade Organization (WTO) to challenge the practice of Chinese courts to unilaterally set binding global royalty rates for non-Chinese…
On 9 January 2025 I reported on Parts 1 and 2 of a three-part article in EPI Information by Tamaris Bucher, a Principal Patent Attorney at Novartis Pharma AG, on the current approach to antibody…
